Exemestane 25 mg
25 mg · 30 tablets · Exemestane 25 mg is a powerful steroidal AI for irreversible estrogen suppression — ideal for PCT, testosterone recovery, and advanced hormonal modulation with long-acting PK support.
€ 38.00
Beskrivelse
Exemestane 25 mg
Merkevare: Magnus Pharmaceuticals
Innhold: 30 tablets | 25 mg per tablet
Pris: €38
Manufactured in: Europe
🧪 Produktoversikt
Exemestane 25 mg is a third-generation, steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme, producing sustained suppression of systemic estrogen. Widely used in hormonal modulation and post-cycle therapy (PCT) research, it is particularly effective for testosterone-boosting protocols and estrogen-dependent tumor investigations.
A single 25 mg dose lowers estradiol by 60–80% within 12 hours and sustains suppression for up to 48 hours due to its ~24–27 hour half-life. Studies confirm its effectiveness in raising LH, FSH, and modestly increasing endogenous testosterone without altering adrenal androgens. This compound is listed on WADA’s S4 prohibited list for hormone modulators.
✅ Viktige forskningsresultater
Irreversible aromatase blockade:
Covalently deactivates CYP19, maintaining estrogen suppression post-clearance [ScienceDirect]
24-hour pharmacokinetics:
Half-life of 24–27 hours ensures stable once-daily dosing in long-term hormonal protocols [PubMed]
↑ Testosterone-to-estradiol ratio:
25 mg/day improved T:E ratios in male models without affecting DHEA/androstenedione [FDA data]
Bone & lipid impact (chronic use):
Long-term data show ↓ BMD and HDL↓ / LDL↑ — relevant for extended-duration studies [PubMed, PMC]
Shelf-stable & lab-friendly:
Film-coated tablets remain potent at ≤25 °C without refrigeration [ICH Stability, MSDS]
🧬 Suggested Laboratory Applications
-
Irreversible aromatase inhibition and estrogen-suppression modeling
-
Testosterone enhancement in male hypogonadism models
-
PCT studies for anabolic-recovery protocols
-
LH/FSH modulation research
-
Tamoxifen-resistant estrogen-tumor studies
📊 Tekniske spesifikasjoner
| Felt | Data |
|---|---|
| Kjemisk navn | Exemestane (INN) |
| Kjemisk formel | C<sub>20</sub>H<sub>24</sub>O<sub>2</sub> |
| Synonymer | Aromasin; FCE 24304; 6-methyleneandrosta-1,4-diene-3,17-dione |
| Molekylvekt | 296.4 g/mol |
| CAS-nummer | 107868-30-4 |
| Half-life | ~24–27 hours |
| Detection Window | Medium-long, varies with protocol |
| Documented Benefits | ↓ E2 by 60–80%, ↑ LH/FSH, ↑ T, stable estrogen suppression |
| Main Risks | ↓ BMD, lipid shifts, fatigue, joint pain, hot flashes |
| Total aktiv forbindelse | 750 mg per carton (25 mg × 30 tablets) |
| Shelf-life | 36 måneder (produsentens spesifikasjoner) |
❄️ PubChem-Supported Research Insights
-
Irreversible suppression of estrogen via steroidal aromatase inhibition
-
Rapid E2 reduction within 12 hours of dosing
-
Increases T:E ratio in male subjects without disturbing adrenal steroids
-
Maintains hormonal control for up to 48 hours post-dose
-
Applied in resistant ER+ tumor model studies and androgen support trials
⚠️ Dokumenterte forskningsbivirkninger
-
Common: Hot-flushes, arthralgia, fatigue, insomnia
-
Long-term: Bone mineral density reduction, HDL↓/LDL↑
-
Other: Menopausal symptoms and mood variations
-
Listed under WADA S4 — prohibited in all competitive levels
🧯 Håndtering og etterlevelse
Kun til forskningsbruk — Not for human or veterinary use
Lagre på 15–25 °C, protect from light and moisture
Kjøpet bekreftes qualified researcher status
Listed on WADA Prohibited List S4 — any exposure may result in a positive test
Det er ingen anmeldelser ennå.
